ReviewDer Nervenarzt2026
[Transition: challenges and recommendations for adolescents and young adults with schizophrenia].
Review in Der Nervenarzt, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFirst acute episodes or severe recurrent courses of schizophrenia often occur in the age of transition, the transition between the pediatric psychiatric and the adult psychiatric care systems.
objectiveExamination of the challenges and recommendations for the transition of patients with schizophrenia. MATERIAL AND
methodsA narrative review was carried out taking the current S3 guidelines of the Association of the Scientific Medical Societies in Germany (AWMF) on schizophrenia into consideration.
resultsThe guideline-conform early detection and treatment of schizophrenia is already a challenge independent of the transition. Recommendations on the transition period for clinics and private service providers concern elements of the disorder itself, the structure of the healthcare system and specialized training and culture, and the concepts and financial compensation for treatment transitions.
conclusionThe updated German S3 guidelines on schizophrenia published in 2025 include numerous recommendations for coordinated treatment in the transition phase but in most parts maintain the age cut-off at 18 years. For optimal care in the age for transition, access to specialized early detection and intervention centers is essential. An overlapping treatment during the transition phase and a bidirectional flexibility of age limits within healthcare systems appear to be beneficial in certain cases.
Indexed as
Identifiers
41557032What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.